U.S. markets open in 2 hours 31 minutes
  • S&P Futures

    4,004.00
    +0.75 (+0.02%)
     
  • Dow Futures

    33,970.00
    -16.00 (-0.05%)
     
  • Nasdaq Futures

    11,824.00
    +18.25 (+0.15%)
     
  • Russell 2000 Futures

    1,840.90
    -1.00 (-0.05%)
     
  • Crude Oil

    75.87
    -1.06 (-1.38%)
     
  • Gold

    1,789.50
    +8.20 (+0.46%)
     
  • Silver

    22.71
    +0.29 (+1.31%)
     
  • EUR/USD

    1.0520
    +0.0022 (+0.21%)
     
  • 10-Yr Bond

    3.5990
    0.0000 (0.00%)
     
  • Vix

    20.82
    +1.76 (+9.23%)
     
  • GBP/USD

    1.2218
    +0.0024 (+0.20%)
     
  • USD/JPY

    136.3090
    -0.3760 (-0.28%)
     
  • BTC-USD

    16,985.24
    -322.85 (-1.87%)
     
  • CMC Crypto 200

    400.69
    -10.53 (-2.56%)
     
  • FTSE 100

    7,542.39
    -25.15 (-0.33%)
     
  • Nikkei 225

    27,885.87
    +65.47 (+0.24%)
     

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.

In contrast to all that, many investors prefer to focus on companies like Ergomed (LON:ERGO), which has not only revenues, but also profits. While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing.

See our latest analysis for Ergomed

Ergomed's Improving Profits

In the last three years Ergomed's earnings per share took off; so much so that it's a bit disingenuous to use these figures to try and deduce long term estimates. As a result, we'll zoom in on growth over the last year, instead. Ergomed's EPS skyrocketed from UK£0.20 to UK£0.25, in just one year; a result that's bound to bring a smile to shareholders. That's a fantastic gain of 27%.

It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. Ergomed maintained stable EBIT margins over the last year, all while growing revenue 37% to UK£119m. That's progress.

In the chart below, you can see how the company has grown earnings and revenue, over time. To see the actual numbers, click on the chart.

earnings-and-revenue-history
earnings-and-revenue-history

The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Ergomed's future EPS 100% free.

Are Ergomed Insiders Aligned With All Shareholders?

It should give investors a sense of security owning shares in a company if insiders also own shares, creating a close alignment their interests. So it is good to see that Ergomed insiders have a significant amount of capital invested in the stock. We note that their impressive stake in the company is worth UK£119m. Coming in at 19% of the business, that holding gives insiders a lot of influence, and plenty of reason to generate value for shareholders. So there is opportunity here to invest in a company whose management have tangible incentives to deliver.

Should You Add Ergomed To Your Watchlist?

You can't deny that Ergomed has grown its earnings per share at a very impressive rate. That's attractive. This EPS growth rate is something the company should be proud of, and so it's no surprise that insiders are holding on to a considerable chunk of shares. On the balance of its merits, solid EPS growth and company insiders who are aligned with the shareholders would indicate a business that is worthy of further research. We should say that we've discovered 2 warning signs for Ergomed that you should be aware of before investing here.

Although Ergomed certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see insider buying, then this free list of growing companies that insiders are buying, could be exactly what you're looking for.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here